Brought to you by 
Sarepta licenses Pompe program from Lacerta, options two CNS candidates
23 Aug 2022
Executive Summary
Sarepta Therapeutics Inc. licensed exclusive worldwide rights to Lacerta Therapeutics Inc.'s gene therapy candidate for Pompe disease (an autosomal recessive metabolic disorder which damages muscle and nerve cells) and has options to license two additional neuro-focused candidates from Lacerta's pipeline.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Technologies
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sarepta licenses Pompe program from Lacerta, options two CNS candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice